FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

PhRMA Comments on FDA Safety Reporting Guide

[ Price : $8.95]

PhRMA tells FDA it appreciates many of the revisions the agency has made to a draft guidance on sponsor responsibilities for safet...

Priority Review for ViiVs Cabotegravir HIV Preventer

[ Price : $8.95]

FDA grants priority review to ViiVs cabotegravir to prevent acquisition of HIV in certain men.

Affordable Healthcare Pleads Guilty in Adulterated Device Case

[ Price : $8.95]

The Justice Department says Affordable Healthcare Solutions pled guilty to one felony count of receiving adulterated medical devic...

Regeneron Libtayo sBLA for Cervical Cancer

[ Price : $8.95]

FDA accepts for review a Regeneron Pharmaceuticals supplemental BLA for PD-1 inhibitor Libtayo (cemiplimab-rwlc) to treat certain ...

Eisai Rolling BLA for Alzheimers Drug

[ Price : $8.95]

Eisai begins a rolling BLA submission for lecanemab, the companys investigational anti-amyloid beta protofibril antibody for treat...

Pfizer Amends Trial Protocol Due to Adverse Events

[ Price : $8.95]

Pfizer submits a clinical trial protocol amendment for a Phase 3 gene therapy trial for fordadistrogene movaparvovec in Duchenne M...

FDA and UK Expand Mutual Recognition Agreement

[ Price : $8.95]

FDA and the United Kingdom expand their ongoing mutual recognition agreement to include animal drug inspections.

Alert on Left Atrial Appendage Occlusion Devices

[ Price : $8.95]

FDA alerts health care providers on recent information about the potential for differences in procedural outcomes between women an...

CDER Head Talks Quality Management Maturity

[ Price : $8.95]

CDER director Patrizia Cavazzoni tells an industry conference that agency inspectors are emphasizing the importance of having in p...

Enforcement Discretion for Certain IVD Studies

[ Price : $8.95]

FDA says it intends to exercise enforcement discretion regarding a requirement for informed consent for in vitro diagnostic device...